FindTrial
Sign In

Role of Vasavaleha in Pulmonary Tuberculosis as an adjuvant therapy

Role of Vasavaleha in Pulmonary Tuberculosis as an adjuvant therapy- A Randomised Placebo Controlled Clinical Trial

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2022/01/039485
Enrollment
26
Registered
2022-01-17
Start date
Unknown
Completion date
Unknown
Last updated
2022-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: A150- Tuberculosis of lung

Interventions

None listed

Sponsors

KLE Academy of Higher Education and Research Belagavi
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1. Newly diagnosed cases of Pulmonary Tuberculosis confirmed by sputum smear and culture or positive for AFB by molecular testing (Expert). 2. Age between 18 yrs and 65 yrs and willing to provide informed consent. 3. Agreement to participate in the study and to give a sample of sputum and blood for lab investigations.

Exclusion criteria

Exclusion criteria: 1. Persons with HIV (PLHIV), Diabetes Mellitus, malnourished, cancer and patients on immunosuppressant or maintenance steroid therapy. 2. Extra-pulmonary TB patients. 3. Pregnant and lactating women.

Design outcomes

Primary

MeasureTime frame
Add on efficacy w.r.t sputum conversion rateTimepoint: At the interval of 1 month and final assessment at the end of 3 months—

Secondary

MeasureTime frame
Improvement in body weight and Quality of lifeTimepoint: At the interval of 1 month and final assessment at the end of 3 months—

Countries

India

Contacts

Public ContactDivya Khare

KAHERs Shri B. M. Kankanawadi Ayurveda Mahavidyalaya, Shahapur, Belagavi

divyakhare2008@gmail.com09731068468

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026